REG - SkinBioTherapeutics - Placing of Shares

SkinbiotherapeuticsAnnouncement

15/11/2021 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211115:nRSO3074Sa&default-theme=true

RNS Number : 3074S  SkinBioTherapeutics PLC  15 November 2021

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Placing of shares held by major shareholder

 

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin
health, has today been informed that its major shareholder, OptiBiotix Health
Plc ("OptiBiotix") has placed 3,636,363 ordinary shares in SkinBioTherapeutics
with new and existing institutional investors at a price of 55 pence per
share.  Prior to the sale OptiBiotix held 36,138,569 ordinary shares
representing 23.1% of the Company and following this sale, will continue to
hold 32,502,206 ordinary shares in SkinBioTherapeutics representing 20.7% of
the Company.

Optibiotix, Cenkos Securities Plc and the Company have entered into a lock-in
and orderly market agreement pursuant to which Optibiotix has undertaken to
the Company and to Cenkos that, subject to the customary exceptions: (i) it
will not until the first anniversary of the sale dispose of the Ordinary
Shares that it holds during such period; and (ii) it will only dispose of such
Ordinary Shares during the 12 month period following such first anniversary
through the Company's Nominated Adviser and Broker so as to ensure an orderly
market in the Shares.

Stuart Ashman, CEO of SkinBioTherapeutics, said:

"We are pleased that this placing is enabling us to bring in new institutional
shareholders and broadening the shareholder base in an orderly fashion. The
Company is going from strength to strength with its newly launched first
commercial product, AxisBiotix-Ps™, so it is important to attract new
investors who are keen to come on board to support us in the next stage of the
Company's development, as a commercial entity."

-Ends-

For more information please contact:

 SkinBioTherapeutics plc                                  Tel: +44 (0) 161 468 2760

 Stuart J . Ashman, CEO

 Doug Quinn, CFO
 Cenkos Securities Plc (Nominated Adviser & Broker)       Tel: +44 (0) 20 7397 8900

 Giles Balleny, Max Gould (Corporate Finance)

 Michael Johnson, Dale Bellis (Sales)
 Instinctif Partners (financial press)                    Tel: +44 (0) 20 7457 2020

 Melanie Toyne-Sewell / Nathan Billis                     SkinBio@instinctif.com (mailto:SkinBio@instinctif.com)

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AsixBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis was launched on 29 October - World
Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For
more information, visit: www.skinbiotix.com (http://www.skinbiotix.com/)  .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEBCBDBBBBDGBS